PTO/AlA/lS (031-13;-
`Approved for use through (ll/'31.,I'2014 OMB 0651—0032
`U. S. Patent and Trademark Office 1
`‘i DEPARTMENT OF COi‘J‘iMERClE
`
`Under the Pa" erwork Reduction Act. of 1935 no ersons are rec uired to res wind to a collection 0. inforIIEIdtion unless 11 mania s a vaiid OMB coIItroi number
`
`
`1.5111111”
`1;861. 27DQDG§IJMCliViSB
`FATENT APPLECAT§QN
`First rimmed/mentor EAEexander OKSCHE
`
`
`
`TRANEM EWAL
`Bupren-z113111116-Wafer for 13111911111101: Therapy
`
`Express Mail Label No
`(Only/far new nonprovislonai appilcatlons under 37 CFR 153(k)}
`
`
`
`
`APPLECA‘E‘EQN ELEMEN'E'S
`See MPEP chapter 600 concerning utility patent application contents.
`
`ADDRESS T0:
`
`Commissioner for Patents
`9-01 333‘ 1450
`Alexandria, VA 22313—14511
`
`11D Fee Transmittal mm
`(PTO/SW17 or equivalent]
`
`ACCGMPANWNG APPHCATEGN PAPERS
`
`2. [—1 Applicant asserts small entity status.
`""" See 37 cm 1,27
`
`10‘ i
`
`Assignment i’apers
`(cover sheet 8. documentijsfl
`
`
`3. D Applicant certifies micro entity status. See .37 cm 219,
`Appiicani‘ must. attachIorm 1—",10/518/251313. or is o- equivaient.
`
`[Total Pages 25
`4. [7] Specification
`Both the claims and abstract must start on a new page.
`(See MPEP 9' 603.01 {11),er information on the preferred arrangement)
`5. m Drawingis} (35 U.S.C. 113')
`{Total Sheets
`1
`
`ES.
`inventor’s Oath or Declaration
`{Total Pages "6
`(including substitute statements under 37 CFR 1.64 and ass
`
`
`]
`
`serving as an oath or decimation unde.'37 CFR 163(9),)
`a. E Newly executed!1or1ginal or copy)
`b.
`1'
`1 A copy from a prior application (37 CFR 1.63(d)_)
`Appiication Data Sheet
`* See note below.
`
`See 37 CFR 1.761'PT01’AIA/14 or equivalent)
`C9~RQM or CD41
`8.
`
`Name at Ass1gnee ---------------------------------------------------------
`_______________________________________________________________________________________
`
`11.
`
`1..
`
`37 CFR 3.73M Statement
`(when there is an asygnee‘)
`
`[UK] English Translation Document
`
`13.
`
`1’
`
`(ifapp/icobic)
`information Disciosure Statement
`(PTO/SB/OS or PTO» 1449}
`
`E i’ower of Attorney
`
`E] Copies of citations attached
`14 a Preliminary Amendment
`15, 1'"" Return Receipt Postcard
`(MPEP § 503) (Should be specifically itemized)
`Certified Copy of Priority Documentisi
`.]foreign priority is claimed)
`
`15
`
`17
`
`in duplicate, large table, or computer Program (Appendix)
`1 Landsca 2e Table on CD
`l]
`9. Nucleotide and/or Amino Acid Sequence Submission
`(if applicable. items a.
`c. are required)
`a. 1
`Computer Readable Form (CRF‘;
`1.3
`111:] Specification Sequence Listing on:
`iCD-ROMG.CDR’7cop1s,: or
`ii.l:| Paper
`
`11m Statements verifying identity of above cor, __
`111.1.
`*Note:
`)Benefit c'airns under 37 CFR i .78. and foreign priority claims under 1 551111.151“ be included in an Application Data Sheet (ADS).
`(2
`)For apphcations filed under75 U S C 111, the application must contain an ADS spe. cying the applicant if the applicant is an
`asignee, person to whom the inventor15 under 81'oiigation to assign, or person who otherwise shows sufficient proprietary
`interest in the matter. See 37 CFR 1. 4131111.
`19. CGRRESEGNDENCE ADDRESS
`
`Nonpublication Request
`Under 351.}S. C.2.2(h)(2 113,111). Applicant. mustattach foam PTG/SB/3S
`o1 equivalent.
`Other: Auihn
`1531
`
`Certification and Request for Prioritized Examination (Track 1); and
`The U S. Paien1& Trademark Office is hereby authorized to charge anyiee
` tI Account No.
`
`
`
`
`
`953 associated with Customer Number: 101416
`
`DR U Correspondence address below
`
`
`
`“—
`—
`liiliatinewS Bodensieinl
`Sepien1o8r18,2017 E'
`Matthews}. Bodensiein
`aflflf‘ N51, 58,885
`
`
`ion oI inforrI
`tion is red redby 37 CFR“.153,l Their1formatior1'1s required to obtain or retaina hen it by the public wh
`s to file (and by the USPTO
`This coile
`
`
`to process: an application. Confide..tiaii
`govemed'by 35 U. S. C. 122 and 37 CFR 1-1 andi1.4. This collection1: estimated to talt'L 12 minuth to complete,
`i..ciuding gat..er1ng, perari..g, and sub...itti..gthe compiLtLd appiication 1'01.1n to thL USPTO. Time will va1y depending upon theindividuaic;se.Ar1y comments on
`
`the amount of time you requhe to compiete this form and/or suggestions for reducing this butclm, should be sent to the Chief information Officer, US Patent and
`Trademark Office, U.S. Department of Commerce, PO. Box 1450,1’xiexandr1a.\iA 22313-1450. DO NOT SEND FEES 0P. COMPLETED FORMS T0 THiS ADDRESS. SEND
`T0: Commissioner for Patents, 13.0. Eiox 145KB, Alexandria, VA 22313-1450.
`lfyou need assistance in completing thefarm, call1-800—P7‘0—9199 and .seiect option 2.
`
`
`
`